PML Antibody (5G191): sc-71910

PML Antibody (5G191) is a mouse monoclonal IgG1 antibody that detects PML in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. PML, or promyelocytic leukemia protein, is a crucial zinc finger transcription factor that plays a significant role in regulating gene expression and maintaining cellular homeostasis. PML (5G191) antibody targets proteins primarily located in the nucleus, where PML is involved in various cellular processes, including apoptosis, cell cycle regulation, and DNA damage response. The proper localization of PML is essential for function, as PML forms nuclear bodies that are implicated in the regulation of transcription and the response to stress signals. Disruption of PML localization can lead to pathological conditions, including acute promyelocytic leukemia, where the PML/RARα fusion protein interferes with normal differentiation and promotes oncogenesis. Anti-PML antibody (5G191) enables researchers to gain insights into PML′s role in cellular processes and implications in cancer biology, making PML (5G191) monoclonal antibody a valuable research tool.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

PML Antibody (5G191) References:

1. The promyelocytic leukemia (PML) protein suppresses cyclin D1 protein production by altering the nuclear cytoplasmic distribution of cyclin D1 mRNA.  |  Lai, HK. and Borden, KL. 2000. Oncogene. 19: 1623-34. PMID: 10763819
2. Mitotic accumulations of PML protein contribute to the re-establishment of PML nuclear bodies in G1.  |  Dellaire, G., et al. 2006. J Cell Sci. 119: 1034-42. PMID: 16492707
3. PML protein expression in hereditary and sporadic breast cancer.  |  Plevová, P., et al. 2007. Neoplasma. 54: 263-8. PMID: 17822314
4. Adenovirus type 5 E4 Orf3 protein targets promyelocytic leukaemia (PML) protein nuclear domains for disruption via a sequence in PML isoform II that is predicted as a protein interaction site by bioinformatic analysis.  |  Leppard, KN., et al. 2009. J Gen Virol. 90: 95-104. PMID: 19088278
5. PML protein as a prognostic molecular marker for patients with esophageal squamous cell carcinomas receiving primary surgery.  |  Yen, CC., et al. 2011. J Surg Oncol. 103: 761-7. PMID: 21240990
6. Solubility shift and SUMOylaltion of promyelocytic leukemia (PML) protein in response to arsenic(III) and fate of the SUMOylated PML.  |  Hirano, S., et al. 2015. Toxicol Appl Pharmacol. 287: 191-201. PMID: 26049103
7. Phenylarsine Oxide Can Induce the Arsenite-Resistance Mutant PML Protein Solubility Changes.  |  Jiang, YH., et al. 2017. Int J Mol Sci. 18: PMID: 28125064
8. Integrity of zinc finger motifs in PML protein is necessary for inducing its degradation by antimony.  |  Yang, C., et al. 2019. Metallomics. 11: 1419-1429. PMID: 31313788
9. Conformational exchange at a C2H2 zinc-binding site facilitates redox sensing by the PML protein.  |  Bregnard, TA., et al. 2023. Structure. 31: 1086-1099.e6. PMID: 37473756
10. PML protein expression in hematopoietic and acute promyelocytic leukemia cells.  |  Daniel, MT., et al. 1993. Blood. 82: 1858-67. PMID: 8400236

The preferred PML antibody is PML Antibody (PG-M3): sc-966.